NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.13 -2.80 (-3.42%) GOLD FUTURES
2,330.20 +27.30 (+1.19%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,200.48 -1,863.49 (-3.88%)
GlaxoSmithKline plc (GSK.L)
| Previous close | 1,673.00 |
| Open | 1,685.50 |
| Bid | 1,650.00 x 0 |
| Ask | 1,710.00 x 0 |
| Day's range | 1,673.00 - 1,718.50 |
| 52-week range | 1,302.60 - 1,725.81 |
| Volume | |
| Avg. volume | 8,394,194 |
| Market cap | 69.667B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 14.21 |
| EPS (TTM) | 1.20 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 0.64 (3.83%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
PA Media: MoneyGSK raises profit guidance as vaccine demand grows
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
ZacksGSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
